The objective of this study was to investigate the relationship between methylation patterns of the histone deacetylase 4 gene and eating disorders in a site previously associated with anorexia nervosa (AN). Women with AN (N = 28) or bulimia nervosa (BN) (N = 19) were agematched and sex-matched to controls (N = 45). We obtained saliva-derived DNA and use bisulfite pyrosequencing to examine region-specific methylation differences between cases and controls. The region assayed includes 15 CpGs. We found no significant association between the previously implicated CpG and either AN or BN. We found that three CpGs were nominally associated with AN (P = 0.02-0.03); the largest difference was a 9% hypermethylation in AN. One CpG was nominally associated with BN (P = 0.04), with 4% hypomethylation. None of these results remained significant after correction for multiple testing. We did not replicate previous findings, though through expanded coverage, we identified additional CpGs that were nominally associated with eating disorders. Psychiatr Genet 28:12-15
Introduction
Epigenetic modifications like DNA methylation, whereby a methyl group is tagged to a CpG dinucleotide, have been studied in anorexia nervosa (AN) at the global genome-level (Frieling et al., 2007; Kim et al., 2014) and in candidate gene studies, largely through investigation of promoter regions of genes such as LEP, BDNF, SLC6A4, and POMC (Ehrlich et al., 2010; Pjetri et al., 2013) . Yet, to date, methylation differences at the global genome-level or within candidate genes have not been replicated.
Two recent lines of evidence suggest that histone deacetylase 4 (HDAC4), which encodes a repressor of transcription factors, might be one gene implicated in the epigenetics of eating disorders (ED). First, through linkage and whole-exome sequencing of two large families with AN, Cui et al. (2013) found that an exonic missense mutation A786T in HDAC4 was associated with AN and predicted to have deleterious effects. The same team further demonstrated that female mice heterozygous for the same mutation display several feeding and behavioral deficits (Lutter et al., 2017) . Second, a study led by Booij et al. (2015) examined methylation in bloodderived DNA across ∼ 450 000 CpGs in 29 individuals with AN as compared with 15 controls. They found that fourteen CpGs survived a false discovery rate cutoff of Q less than 0.05, including one within HDAC4 (genomic location: chr2: 240 171 748, referred to as cg01114124 on the Illumina Infinium HumanMethylation450 BeadChip), which showed 6.25% higher methylation in AN cases than in controls (P = 4.57 × 10 − 5
; false discovery rate = 0.045) (Booij et al., 2015) .
HDACs modulate transcriptional regulation in the nucleus, and evidence suggests that the HDAC IIa family, which includes HDAC4, may also regulate substrates independently of deacetylation in the cytoplasm. HDAC4 is involved in energy homeostasis and neuronal plasticity, with widespread distribution in the brain (Darcy et al., 2010; Sando et al., 2012; Clocchiatti et al., 2013) .
Given this evidence, our investigation included three goals: (i) to replicate the finding of hypermethylation at the Booij et al. (2015) . HDAC4 CpG site in a case-control study, (ii) to test the association between AN and nearby CpGs in HDAC4, and (iii) to extend observations to bulimia nervosa (BN).
Participants and methods

Study design
We designed a case-control study using saliva-derived DNA. Case samples were ascertained from the ED inpatient and partial hospital services at the University of Booij et al. (2015) . Clinical information was gathered by research interviews using the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DSM-IV) axis I disorders. The DSM-IV was used to make diagnoses, and BMI at time of onset was recorded. Individuals with binge eating/ purging-AN were excluded.
Controls were obtained from the Tissue Procurement Core at University of Iowa, and samples were approved by the University of Iowa's Institutional Review Board. All participants provided written consent. Individuals were volunteers whom we attempted to match with cases by age, sex, and ethnicity. We matched ages to the nearest age group within 5 years. In the control group, we excluded those with an ED history and those on psychiatric medications at the time of saliva collection. The Tissue Procurement Core provided BMI at time of saliva collection.
Sodium bisulfite treatment and nested PCR
We collected 400 ng of DNA from each participant's sample for bisulfite pyrosequencing. DNA samples were bisulfite converted using the EZ DNA Methylation-Gold Kit (Zymo Research Inc., Irvine, California, USA), according to the manufacturer's instructions.
After bisulfite conversion, we performed nested PCR. The outer PCR amplification was done with 1 μl of bisulfite converted DNA. This was done via Taq polymerase using the PyroMark PCR kit (Qiagen; Germantown, Marryland, USA). Subsequently, 2 μl of each outer region product was used for inner PCR application. One of the primers in each set was biotinylated at the 5′-end and high-performance liquid chromatography purified. Primers were designed using PyroMark Assay Design software SW 2.0 (Qiagen, Germantown, Marryland, USA). For nested PCR primer sequences, refer to Supplementary Table (Supplemental digital content 1, http://links.lww.com/PG/A201). The UCSC Genome Browser, GRCh37/hg19, was used to design primers targeting the DNA region 300 bp upstream and downstream of the coordinate chr2: 240 171 748 (referred to as cg01114124 on the Illumina Infinium HumanMethylation450 BeadChip, San Diego, California, USA), which was previously associated with AN (Kent et al., 2012; Booij et al., 2015) .
Bisulfite-pyrosequencing analysis
Ten unique sequencing primers targeting 15 CpGs were created within the 600 bp region. Sequencing primers are tabulated in Supplementary Table (Supplemental digital content 2, http://links.lww.com/PG/A201). Reactions were conducted using PyroMark Q96 Advanced CpG reagents and a PyroMark Q96 MD instrument (Qiagen, Germantown, Marryland, USA). The pyrograms were analyzed using the CpG mode of the PyroMark Advanced software (Qiagen, Germantown, Marryland, USA) to determine the methylation percentage of each site for cases and for controls.
To determine how reliable our methylation values were at specific sites, we arbitrarily selected sites 62 and 53 bp downstream of coordinate chr2: 240 171 748 and repyrosequenced using DNA from AN cases and controls. There were no statistical differences between the mean percent values when AN cases and matched controls were replicated across methylation assays (P = 0.97 and 0.99 at site − 62; P = 0.72 and 0.92 at site − 53).
Statistical analyses
Age and BMI were compared between cases and controls using a two-tailed Student's t-test. Linear regression was used to evaluate associations of methylation levels with age and BMI. Methylation differences between cases and controls were determined with a two-tailed Student's t-test. We report P values that are uncorrected. However, we also considered whether our results would stand up to correction for testing two methylated regions, given the correlation structure across the CpGs, using two phenotypes (four tests).
Results
Clinical characteristics for cases and controls are summarized in Table 1 . The average (SD) age was 24 (6.1) and 26 (6.3) years in AN cases and controls, respectively. Likewise, the average (SD) age was 22 (5) and 28 (3.8) years in BN cases and controls, respectively. Average (SD) BMI was 16 (1.9), 20 (2.1), 25 (4.5), and 28 (7.8) mg/ kg 2 for AN cases, BN cases, AN-matched controls, and BN-matched controls, respectively. Table 2 presents the bisulfite-pyrosequencing results. Linear regression analyses demonstrated that neither age nor BMI was significantly associated with methylation levels for these CpGs. As a result, we did not control for these in the case-control comparisons of methylation level differences. There was no significant association between AN and the target CpG identified by Booij et al. (2015) . AN cases showed an average (SD) methylation of 93% (3), and controls averaged 94% (3, P > 0.05). However, three adjacent CpG sites showed average methylation levels that were nominally associated with AN case status (P < 0.05). The largest of these differences in methylation between AN cases and controls was 9%. This occurred in a CpG that was hypermethylated in AN, with an average (SD) methylation level of 25% (19) in cases versus 16% (11) in controls. Two nominally associated sites were hypomethylated in AN as compared HDAC4 methylation in eating disorders Subramanian et al. 13
with controls: 85% (6) versus 88% (4), respectively, and 80% (9) versus 85% (8), respectively.
In our bisulfite-pyrosequencing analysis of cases with BN, one unique site was hypomethylated and nominally associated with BN (P < 0.05), with average (SD) methylation of 71% (5) in BN cases versus 75% (7) in controls ( Table 2) . We found neither association nor hypermethylation at the CpG site in BN cases found by Booij et al. (2015) .
Discussion
Using bisulfite pyrosequencing, we assessed 15 CpG sites in HDAC4, and found that four were nominally associated with ED (three with AN and one with BN). Notably, none of these associations withstood correction for multiple testing. We neither replicated the significant differential methylation at the CpG dinucleotide at chr2: 240 171 748 in AN noted by Booij et al. (2015) nor did we observe the consistent hypermethylation across multiple CpGs in AN observed in that report.
Previous results on DNA methylation variation in ED have been mixed. Tremolizzo et al. (2014) noted hypomethylation in whole blood, whereas Saffrey et al. (2014) demonstrated no individual gene or global DNA methylation differences in buccal tissue. These disparate findings may be because of power limitations resulting from the modest number of samples tested in these studies. In addition, methylation patterns may differ across the tissues assayed.
We note that the region we studied is in an intron, whereas the interesting functional variant described by Cui et al. (2013) was in an HDAC4 exon. Intronic genetic and epigenetic variation may alter gene expression or lead to alternative splicing. The largest genome-wide association study of AN, with 5551 AN cases and 21 080 controls, identified two intronic variants (rs9839776 in SOX2OT and rs17030795 in PPP3CA) in their top results, though not at a genome-wide significant level (Boraska et al., 2014) . Analyzing epigenetic differences in intronic regions may aid in the discovery of noncoding regions involved in disease.
We speculate that environmental modifications of HDAC4 might play a pathogenic role in ED and/or associated phenotypes such as anxiety and increased stress reactivity. Recent evidence demonstrates that transgenic mice carrying the HDAC4 missense A778T mutation show sex-specific differences in metabolism and behavior; only females manifested reduced response to high-fat, compulsive grooming, increased weight, and/ or changes in anxiety-like behavior (Lutter et al., 2017) . Another study suggested that overexpression of miRNA-124 leads to behavioral resilience whereas its inhibition leads to increased susceptibility to stress. The authors identified HDAC4 as one of the three targets of miRNA-124 (Higuchi et al., 2016) . Finally, a recent study showed evidence for the involvement of HDAC4 in PTSD in women, and an influence of estrogen on the regulation of Hdac4 in mice (Maddox et al., 2017) .
Several limitations exist in this study. First, our study is cross-sectional; therefore, causation cannot be inferred. Second, although our AN sample had 81% power to detect a methylation difference comparable to that of Booij et al. (2015) , our BN sample had only 66% power to detect methylation differences greater than ten percent. Third, we used saliva-derived DNA, which may or may not reflect epigenetic profiles in the brain, and which differs from the study by Booij et al. (2015) that used blood-derived DNA. Although methylation levels can be tissue specific, many CpGs show methylation levels that are highly correlated across tissues. Although the correlation between saliva and blood at the Booij-examined CpG, cg0111412, is high at 0.824 (P = 1.1 × 10 −7 ) (Smith et al., 2014) , we acknowledge that the use of bloodderived DNA might have led to different results. Fourth, HDAC4 comprises 352 780 bp and differential DNA methylation relevant to AN and BN may exist in the gene's 522 CpGs that we did not assay. Fifth, we did not have data on a number of variables that might have influenced methylation levels, including nonpsychiatric medications, substance use, and smoking status. Oral contraception use in particular is of concern as changes in estrogen levels have been shown to contribute to variation in HDAC4 expression (Maddox et al., 2017) . Sixth, expression levels using RNA were not testable as we had DNA versus tissue samples.
In summary, our study did not find additional support implicating HDAC4 DNA methylation variation in ED; though, we cannot rule out the possibility that limitations in study design could have led to false-negative results.
